Keywords: imclone, erbitux, filed, refractory, colorectal, cancer, usa

ImClone's Erbitux filed for refractory colorectal cancer in USA

Article | 02 November 2001

Print This

ImClone Systems new antibody-based anticancer drug Erbitux (cetuximab;IMC-225) has been filed for approval in the USA in a rolling ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in